Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
October 23, 2023 01:00 ET
|
Roivant Sciences
Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a...
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
September 26, 2023 06:00 ET
|
Roivant Sciences
IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase...
Roivant Announces Completion of Redemption of its Outstanding Warrants
September 11, 2023 08:00 ET
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it completed the redemption of its outstanding public warrants (the “Public...
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
August 17, 2023 16:05 ET
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously...
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
August 14, 2023 07:00 ET
|
Roivant Sciences
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across...
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
August 03, 2023 16:05 ET
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday,...
Roivant Announces Redemption of Outstanding Warrants
August 02, 2023 16:05 ET
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the “Public...
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
July 27, 2023 08:00 ET
|
Roivant Sciences
The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of RVT-3101 in patients with moderate to severely active Crohn’s disease (CD)Roivant recently announced highly...
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
July 11, 2023 08:00 ET
|
Roivant Sciences
BASEL, Switzerland, LONDON, and NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) -- Fast Company today announced its fifth annual Best Workplaces for Innovators list, honoring organizations and businesses...
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
June 28, 2023 08:57 ET
|
Roivant Sciences
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across...